The Democratic Republic of the Congo has recorded 9,066 confirmed Ebola infections and 4,381 deaths since May 2026, making the ongoing outbreak the country's largest and deadliest on record.
The figures, published by Congo's public health institute and reported by Reuters on October 13, mark another milestone in an epidemic caused by Bundibugyo virus, a type of Ebola virus for which no vaccine or virus-specific treatment has been approved.
Health authorities face continuing transmission across multiple provinces, difficulties monitoring exposed people and growing concerns about infections crossing international borders. Meanwhile, researchers are preparing a major vaccine trial that could help determine whether an existing Ebola vaccine offers protection against Bundibugyo virus.
How Severe Is Congo's Ebola Outbreak?
The latest government figures represent a substantial increase from the World Health Organization's October 6 surveillance data, which documented 8,728 confirmed infections and 4,205 deaths.
Comparing those two reporting snapshots shows an increase of 338 confirmed cases and 176 deaths. However, changes in cumulative totals do not necessarily mean every additional infection or death occurred during that seven-day period.
The newly reported totals correspond to a crude case fatality ratio of approximately 48.3%. This measures reported deaths relative to confirmed infections and should not be interpreted as an individual patient's probability of dying. Delayed diagnosis, incomplete case detection and differences in access to medical care can affect the reported ratio.
The outbreak has surpassed Congo's previous worst Ebola epidemic of 2018–2020. Globally, it ranks second behind the 2014–2016 West African epidemic, which involved more than 28,600 reported cases and over 11,000 deaths.
According to the WHO's October 8 outbreak assessment, confirmed infections had reached 64 health zones across seven Congolese provinces as of October 6. More recent reporting from the Associated Press described 65 affected health zones, reflecting the outbreak's expanding geographic footprint.
Why Containing the Outbreak Remains Difficult
Eastern Congo remains the center of the epidemic. In its October 6 assessment, WHO recorded 6,480 confirmed infections in Ituri province and another 1,755 in North Kivu. Transmission intensity varies across affected communities, with some locations showing improvement while others continue to report new infections.
Contact tracing is a critical part of Ebola containment because health teams must identify and monitor people potentially exposed to infected patients.
WHO reported that 23,741 of 29,535 identified contacts had been reached as of October 4, representing approximately 80.4% coverage. That left a substantial surveillance gap in an outbreak where rapid identification and isolation can help interrupt transmission.
Insecurity, population displacement, limited healthcare infrastructure and movement between affected communities have complicated response operations. Mistrust of health authorities and difficulties ensuring safe burials can create additional obstacles.
WHO also highlighted the high proportion of deaths occurring outside treatment centers. Among 372 deaths reported during its latest assessment interval, 264 occurred in communities rather than treatment facilities.
These findings underscore the importance of earlier diagnosis, accessible treatment, community engagement and consistent surveillance. They do not, by themselves, establish how many infections have gone undetected.
What Makes Bundibugyo Ebola Different?
The current epidemic is caused by Bundibugyo virus, which is distinct from the Ebola virus responsible for several previous major outbreaks.
That distinction matters because the licensed Ebola vaccine Ervebo is approved for disease caused by Ebola virus, previously known as Zaire ebolavirus. Its effectiveness against Bundibugyo virus disease has not been established in humans.
WHO and research partners are preparing the Tumaini vaccine trial in Congo to investigate whether Ervebo provides meaningful protection against Bundibugyo infection.
Speaking on October 13, Anthony Scott, chair of WHO's Strategic Advisory Group of Experts on Immunization, said the trial was expected to begin before the end of October. The proposed research framework could also evaluate additional Bundibugyo-specific vaccine candidates, including products under development by teams associated with the University of Oxford and Moderna.
These preparations represent an important research development, but the planned trial has not yet established vaccine efficacy. WHO's August vaccine allocation announcement explained that Ervebo doses were being supplied for clinical research and frontline-worker protection under specific recommendations.
Research into treatments is also underway. WHO-supported investigators began enrolling patients in the PARTNERS clinical trial in July to assess investigational therapies for Bundibugyo virus disease.
Although no virus-specific treatment has been approved, supportive hospital care remains essential. Prompt diagnosis, fluid management, treatment of complications and appropriate infection-control measures can improve patient care and support outbreak containment.
Are Neighboring Countries at Risk?
The epidemic has already produced confirmed infections outside Congo, reinforcing the importance of coordinated regional surveillance.
Uganda recorded 20 infections and two deaths earlier in 2026 before authorities declared its outbreak over in August.
Kenya subsequently confirmed its first imported Bundibugyo infection on October 6. According to WHO, the patient had traveled from Congo through Uganda before arriving in Nairobi on October 3. The patient died on October 5 after receiving hospital care.
Kenyan authorities initiated contact tracing and laboratory surveillance. By October 11, officials reported no additional confirmed infections following 293 tests, as detailed in NewsFusion365's earlier coverage of Kenya's Ebola testing and contact monitoring.
Separately, the Netherlands reported receiving an infected healthcare worker medically evacuated from Congo on October 1. WHO classified the event as a controlled medical evacuation rather than local transmission in the Netherlands.
These incidents demonstrate the possibility of cross-border exposure without establishing sustained community transmission in every country receiving an infected person.
In its October 8 report, WHO maintained a very high risk assessment for Congo, a high assessment for neighboring countries sharing land borders and a low global risk assessment. The organization did not recommend general restrictions on travel or trade with affected countries.
What Health Authorities Are Watching Next
The outbreak's trajectory will depend partly on whether public-health teams can identify infections earlier, strengthen contact monitoring and improve access to treatment in communities experiencing continued transmission.
Important indicators include the number of newly reported infections, deaths occurring outside treatment facilities, geographic expansion and the proportion of exposed contacts successfully monitored.
Regional authorities will also need to maintain coordinated testing and surveillance to identify imported infections promptly while distinguishing isolated cases from local transmission.
The anticipated Tumaini vaccine trial offers a potential path toward stronger evidence about vaccination against Bundibugyo virus. However, its planned launch should not be confused with demonstrated effectiveness or regulatory approval.
For now, the latest figures highlight an exceptionally severe epidemic whose containment requires sustained medical resources, reliable surveillance, community cooperation and cross-border public-health coordination.
0 Comments